B7-H3-CAR T Cells

Phase 1Cell therapy

SSt. Jude Children's Research Hospital

B7-H3-CAR T Cells is one of 53 small molecule programs targeting Relapsed/Refractory. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractoryRecruiting

Central Nervous System NeoplasmsActive, not recruiting

Relapsed/refractoryPhase 1

Recruiting

Central Nervous System NeoplasmsPhase 1

Active, not recruiting

Competition

Competitive Landscape

62 competitors in Relapsed/refractory

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

9 2

Rituxan

Roche

Phase 2

9 3

Venclexta

AbbVie

Phase 2

8 4

Fludara

Sanofi

Phase 2

7 5

Keytruda

Merck & Co.

Phase 2

4 6

Opdivo

Bristol-Myers Squibb

Phase 2

4 7

Gemzar

Johnson & Johnson

Phase 2

2 8

Adcetris

Pfizer

Phase 2

2 9

Mektovi

Pfizer

Phase 2

1 10

Thalomid

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Patients With Solid Tumors

NCT04897321

Q1 2028

Phase 1Active, not recruiting

Central Nervous System Neoplasms

NCT05835687

Q4 2031

Phase 1Recruiting

Relapsed/refractory

NCT07222735

Clinical

Trials by Indication[1]

Patients With Solid Tumors1 trial

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT04897321·32 enrolled

Relapsed/Refractory1 trial

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07222735·42 enrolled

Central Nervous System Neoplasms1 trial

Loc3CAR: Locoregional Delivery of B7-H3-specific Chimeric Antigen Receptor Autologous T Cells for Pediatric Patients With Primary CNS Tumors

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT05835687·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for B7-H3-CAR T Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — B7-H3-CAR T Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for B7-H3-CAR T Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: SSt. Jude Children's Research Hospital

B7-H3-CAR T Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Q4 2031

Trials by Indication[1]

Patients With Solid Tumors1 trial

Relapsed/Refractory1 trial

Central Nervous System Neoplasms1 trial

References

Drug Info

Quick Facts

Related News